Last updated: February 19, 2026
Who supplies vutrisiran sodium globally?
Vutrisiran sodium, an RNA interference therapy developed by Alnylam Pharmaceuticals, is supplied primarily through licensed manufacturing partners. As of 2023, these entities include specialized biologics contract manufacturing organizations (CMOs) with capabilities in oligonucleotide synthesis and stabilization.
Manufacturing and supply chain overview
Key suppliers and partners
| Supplier / Partner |
Location |
Role |
Capacity / Notes |
| Alnylam Pharmaceuticals (In-house) |
USA |
Primary developer, initial production |
Maintains internal GMP facilities |
| Lonza |
Switzerland / USA |
CMO for oligonucleotide synthesis |
Capable of large-scale manufacturing |
| Samsung Biologics |
South Korea |
Possible CMO involvement |
Known for biologics manufacturing capacity |
| Thermo Fisher Scientific (via OEM) |
USA / worldwide |
Custom equipment, reagents |
Supplies reagents and synthetic oligonucleotides |
Production specifics
Vutrisiran is a synthetic siRNA conjugated with N-acetylgalactosamine (GalNAc). Its manufacturing involves multiple steps:
- Synthesis of nucleic acid sequences via solid-phase synthesis.
- Chemical modifications to enhance stability and delivery.
- Conjugation to targeting molecules (GalNAc).
- Purification and formulation under GMP conditions.
The process involves over 80 quality control parameters to meet regulatory standards.
Supply constraints and considerations
- The complexity of oligonucleotide synthesis limits rapid scale-up.
- Raw material supply chains, including phosphoramidites and specialized reagents, can create bottlenecks.
- The specialized nature of conjugation and purification facilities restricts the pool of capable CMOs.
Geographic distribution of suppliers
Major suppliers are concentrated in North America, Europe, and Asia. The in-house production by Alnylam prioritizes North American and European markets, while CMOs, such as Lonza and Samsung, extend capacity globally.
Regulatory and quality standards
Supply agreements focus on GMP compliance, batch consistency, and traceability. Suppliers must adhere to guidelines set by the FDA, EMA, and other authorities, which influences supplier selection and qualification.
Summary
The supply of vutrisiran sodium relies on a limited number of specialized CMOs with oligonucleotide production expertise. It involves complex synthesis, conjugation, and purification steps, which limit the number of capable vendors and can impact supply chain agility.
Key Takeaways
- Major suppliers include Alnylam (in-house), Lonza, and Samsung Biologics.
- Manufacturing involves complex synthesis, chemical modification, and conjugation processes.
- Supply constraints stem from the specialty of oligonucleotide production and regulation.
- Geographic distribution of suppliers is concentrated in North America, Europe, and Asia.
- GMP compliance and quality control are critical to supply chain integrity.
FAQs
1. Are there alternative suppliers for vutrisiran sodium?
Currently, no widely available alternative suppliers exist beyond those with specialized oligonucleotide manufacturing capabilities.
2. What factors influence supply chain disruptions for vutrisiran?
Raw material availability, manufacturing complexity, regulatory approvals, and capacity limitations influence disruptions.
3. How long does it take to scale up production of vutrisiran?
Scaling from pilot to commercial-scale production can take 6 to 12 months, depending on capacity and process optimization.
4. Are there regional regulations impacting manufacturing?
Yes. GMP standards and import/export restrictions influence supplier choices and logistics.
5. Can new suppliers enter the vutrisiran supply chain?
Entry requires substantial investment in GMP-compliant oligonucleotide synthesis facilities and regulatory approval, limiting near-term new entrants.
Citations
- Alnylam Pharmaceuticals. (2023). Vutrisiran product information.
- Lonza. (2023). Capabilities in oligonucleotide manufacturing.
- U.S. Food and Drug Administration. (2022). Guidance for oligonucleotide drug manufacturing.
- European Medicines Agency. (2022). Regulation of nucleic acid therapeutics.
